首页 > 最新文献

Journal of Ayurveda and Integrative Medicine最新文献

英文 中文
Efficacy of Berberis vulgaris and Berberis integerrima on glycemic indices and weight profile in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials 小檗和非洲小檗对 2 型糖尿病患者血糖指数和体重状况的疗效:随机对照试验的系统回顾和荟萃分析
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.101039
Hassan ul Hussain , Eman Ali , Areesha Tanveer , Syed Muhammad Ismail , Humam Furqan , Muhammad Nadeem Ahsan , Sadia Iqbal , Muhammad Sohaib Asghar
Type 2 diabetes mellitus (T2DM) is a multifactorial lifelong condition. Berberis vulgaris (BV) and Berberis integerrima (BI) regulate glucose levels with minimal adverse effects. In this systematic review and meta-analysis, we evaluate the effect of BV and BI on glycemic indices, weight, and body mass index (BMI) against placebo.
Four electronic databases were searched till September 24, 2023. Inclusion criteria for studies were: (a) T2DM patients; (b) berberis (vulgaris/integerrima) therapy as intervention; (c) control group of placebo or metformin; (d) outcomes including fasting blood glucose (FBG) levels, glycated hemoglobin (HbA1c%), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), fasting serum insulin (FSI), 2-h postprandial glucose (2hPPG), fructosamine, weight, and BMI; (e) randomized controlled trials (RCTs). Data was pooled using a random-effects analysis model on Review Manager. The inverse variance statistical method was applied keeping weighted mean difference (WMD) as the effect measure. The Cochrane risk of bias tool evaluated the risk of bias. A p-value of less than 0.05 was considered significant.
Nine RCTs comprising 547 patients were included. Significant reduction was noted with berberis therapy in FBG (WMD: −14.52; 95% CI = −22.97, −6.07; P = 0.0008); HbA1c % (WMD: −0.30; 95% CI = −0.53, −0.07; P = 0.01); HOMA-IR (WMD: −0.97; 95% CI = −1.56, 0.37; P = 0.001). No significant differences were noted between the two groups in 2hPPG (WMD: 6.52; 95% CI = −21.57, 34.61; P = 0.65); FSI (WMD: −0.79; 95% CI = −1.80, 0.22, P = 0.13); Fructosamine (WMD: −12.57; 95% CI = −40.74, 15.60; P = 0.38); Weight (WMD: −1.89; 95% CI = −4.55, 0.76; P = 0.16) and BMI (WMD: −0.12; 95% CI = −0.90, 0.65; P = 0.76).
The data showed significant reduction in FBG and improved insulin levels but limited effects were observed in other glycemic indexes. More extensive RCTs are required globally to achieve a holistic comprehension of the connection between berberis and T2DM.
2 型糖尿病(T2DM)是一种多因素的终身疾病。小檗(BV)和非洲小檗(BI)可调节血糖水平,且不良影响极小。在本系统综述和荟萃分析中,我们评估了 BV 和 BI 与安慰剂相比对血糖指数、体重和体重指数(BMI)的影响。研究的纳入标准为(a) T2DM 患者;(b) 以小檗(庸俗草/integerrima)疗法作为干预措施;(c) 对照组为安慰剂或二甲双胍;(d) 结果包括空腹血糖 (FBG)水平、糖化血红蛋白 (HbA1c%)、胰岛素抵抗静态模型评估 (HOMA-IR)、空腹血清胰岛素 (FSI)、餐后 2 小时血糖 (2hPPG)、果糖胺、体重和体重指数 (BMI); (e) 随机对照试验 (RCT)。数据采用《综述管理器》上的随机效应分析模型进行汇总。采用反方差统计方法,将加权平均差(WMD)作为效果测量指标。科克伦偏倚风险工具对偏倚风险进行了评估。九项研究纳入了 547 名患者。小檗治疗显著降低了FBG(WMD:-14.52;95% CI = -22.97,-6.07;P = 0.0008);HbA1c %(WMD:-0.30;95% CI = -0.53,-0.07;P = 0.01);HOMA-IR(WMD:-0.97;95% CI = -1.56,0.37;P = 0.001)。两组在 2hPPG (WMD:6.52;95% CI = -21.57,34.61;P = 0.65);FSI(WMD:-0.79;95% CI =-1.80,0.22,P = 0.13);果糖胺(WMD:-12.57;95% CI =-40.74,15.60;P = 0.数据显示,FBG 显著降低,胰岛素水平得到改善,但对其他血糖指数的影响有限。要全面了解小檗与 T2DM 之间的关系,还需要在全球范围内开展更广泛的 RCT 研究。
{"title":"Efficacy of Berberis vulgaris and Berberis integerrima on glycemic indices and weight profile in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials","authors":"Hassan ul Hussain ,&nbsp;Eman Ali ,&nbsp;Areesha Tanveer ,&nbsp;Syed Muhammad Ismail ,&nbsp;Humam Furqan ,&nbsp;Muhammad Nadeem Ahsan ,&nbsp;Sadia Iqbal ,&nbsp;Muhammad Sohaib Asghar","doi":"10.1016/j.jaim.2024.101039","DOIUrl":"10.1016/j.jaim.2024.101039","url":null,"abstract":"<div><div>Type 2 diabetes mellitus (T2DM) is a multifactorial lifelong condition. <em>Berberis vulgaris</em> (BV) and <em>Berberis integerrima</em> (BI) regulate glucose levels with minimal adverse effects. In this systematic review and meta-analysis, we evaluate the effect of BV and BI on glycemic indices, weight, and body mass index (BMI) against placebo.</div><div>Four electronic databases were searched till September 24, 2023. Inclusion criteria for studies were: (a) T2DM patients; (b) berberis (vulgaris/integerrima) therapy as intervention; (c) control group of placebo or metformin; (d) outcomes including fasting blood glucose (FBG) levels, glycated hemoglobin (HbA1c%), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), fasting serum insulin (FSI), 2-h postprandial glucose (2hPPG), fructosamine, weight, and BMI; (e) randomized controlled trials (RCTs). Data was pooled using a random-effects analysis model on Review Manager. The inverse variance statistical method was applied keeping weighted mean difference (WMD) as the effect measure. The Cochrane risk of bias tool evaluated the risk of bias. A p-value of less than 0.05 was considered significant.</div><div>Nine RCTs comprising 547 patients were included. Significant reduction was noted with berberis therapy in FBG (WMD: −14.52; 95% CI = −22.97, −6.07; P = 0.0008); HbA1c % (WMD: −0.30; 95% CI = −0.53, −0.07; P = 0.01); HOMA-IR (WMD: −0.97; 95% CI = −1.56, 0.37; P = 0.001). No significant differences were noted between the two groups in 2hPPG (WMD: 6.52; 95% CI = −21.57, 34.61; P = 0.65); FSI (WMD: −0.79; 95% CI = −1.80, 0.22, P = 0.13); Fructosamine (WMD: −12.57; 95% CI = −40.74, 15.60; P = 0.38); Weight (WMD: −1.89; 95% CI = −4.55, 0.76; P = 0.16) and BMI (WMD: −0.12; 95% CI = −0.90, 0.65; P = 0.76).</div><div>The data showed significant reduction in FBG and improved insulin levels but limited effects were observed in other glycemic indexes. More extensive RCTs are required globally to achieve a holistic comprehension of the connection between berberis and T2DM.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101039"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of quality parameters and preservative concentrations in Sahacharadi Kwatha: A comparative study of three commercial brands Sahacharadi Kwatha 的质量参数和防腐剂浓度分析:三种商业品牌的比较研究
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.101029
Sangeetha Gopal, Leon Ittiachen

Background

Sahacharadi Kwatha is traditionally employed in Ayurvedic therapy for "vata" related conditions such as back pain, herniated disc, palsy, sciatica, and paralysis. Classical Ayurvedic texts recommend the use of freshly prepared Kwatha for optimal patient benefits. However, in response to the commercialization of Ayurveda and the demand for convenient over-the-counter (OTC) formulations, various commercial preservatives have been incorporated by Ayurvedic manufacturers to facilitate OTC preparation and prolong shelf life.

Objectives

This study aims to comprehensively analyse and compare the quality parameters and preservative content in three prominent brands of Sahacharadi Kwatha available in the Indian market.

Materials and methods

Organoleptic and physicochemical properties, phytochemical content, and microbial load of the samples were analyzed following standardized procedures. Sodium benzoate levels in the samples were determined using both titrimetric and High-Performance Liquid Chromatography (HPLC) methods. High-Performance Thin-Layer Chromatography (HPTLC) profiles were compared to discern differences among the samples.

Results

The study revealed significant variations in organoleptic and physicochemical properties, HPTLC profiles, and microbial load among the tested samples. Sodium benzoate levels in all samples exceeded the FDA and API-approved limit. Additionally, substantial variations were noted in the phytochemical content of the samples.

Conclusion

This investigation underscores noteworthy disparities in quality parameters and preservative content within the tested market variants of Sahacharadi Kwatha. The findings emphasize the existence of unregulated standards in the preparation of Ayurvedic medicines available in the market, highlighting the imperative for standardization and validation of Ayurvedic formulations. Such measures are essential for enhancing consumer acceptability and fostering the overall development and growth of the Ayurveda industry.
背景Sahacharadi Kwatha 传统上用于阿育吠陀疗法,治疗与 "瓦塔 "有关的疾病,如背痛、椎间盘突出、麻痹、坐骨神经痛和瘫痪。经典的阿育吠陀经文建议使用新鲜制备的 Kwatha,以使患者获得最佳疗效。然而,随着阿育吠陀的商业化和对方便的非处方药(OTC)配方的需求,阿育吠陀制造商加入了各种商业防腐剂,以方便非处方药的制备并延长保质期。本研究旨在全面分析和比较印度市场上三种著名品牌的 Sahacharadi Kwatha 的质量参数和防腐剂含量。使用滴定法和高效液相色谱法测定了样品中的苯甲酸钠含量。研究结果表明,被测样品在感官和理化特性、HPTLC 图谱以及微生物量方面存在显著差异。所有样品中的苯甲酸钠含量都超过了 FDA 和 API 批准的限值。此外,样品中的植物化学成分含量也存在很大差异。调查结果表明,市场上阿育吠陀药物的制备标准不规范,因此必须对阿育吠陀配方进行标准化和验证。这些措施对于提高消费者的接受度、促进阿育吠陀产业的整体发展和增长至关重要。
{"title":"Analysis of quality parameters and preservative concentrations in Sahacharadi Kwatha: A comparative study of three commercial brands","authors":"Sangeetha Gopal,&nbsp;Leon Ittiachen","doi":"10.1016/j.jaim.2024.101029","DOIUrl":"10.1016/j.jaim.2024.101029","url":null,"abstract":"<div><h3>Background</h3><div><em>Sahacharadi Kwatha</em> is traditionally employed in Ayurvedic therapy for \"vata\" related conditions such as back pain, herniated disc, palsy, sciatica, and paralysis. Classical Ayurvedic texts recommend the use of freshly prepared Kwatha for optimal patient benefits. However, in response to the commercialization of Ayurveda and the demand for convenient over-the-counter (OTC) formulations, various commercial preservatives have been incorporated by Ayurvedic manufacturers to facilitate OTC preparation and prolong shelf life.</div></div><div><h3>Objectives</h3><div>This study aims to comprehensively analyse and compare the quality parameters and preservative content in three prominent brands of <em>Sahacharadi Kwatha</em> available in the Indian market.</div></div><div><h3>Materials and methods</h3><div>Organoleptic and physicochemical properties, phytochemical content, and microbial load of the samples were analyzed following standardized procedures. Sodium benzoate levels in the samples were determined using both titrimetric and High-Performance Liquid Chromatography (HPLC) methods. High-Performance Thin-Layer Chromatography (HPTLC) profiles were compared to discern differences among the samples.</div></div><div><h3>Results</h3><div>The study revealed significant variations in organoleptic and physicochemical properties, HPTLC profiles, and microbial load among the tested samples. Sodium benzoate levels in all samples exceeded the FDA and API-approved limit. Additionally, substantial variations were noted in the phytochemical content of the samples.</div></div><div><h3>Conclusion</h3><div>This investigation underscores noteworthy disparities in quality parameters and preservative content within the tested market variants of <em>Sahacharadi Kwatha</em>. The findings emphasize the existence of unregulated standards in the preparation of Ayurvedic medicines available in the market, highlighting the imperative for standardization and validation of Ayurvedic formulations. Such measures are essential for enhancing consumer acceptability and fostering the overall development and growth of the Ayurveda industry.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101029"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of the best plant ratios for a polyherbal tea mix to obtain optimum antioxidant, antidiabetic, and β-glucuronidase inhibition activities 确定多草药茶混合物的最佳植物配比,以获得最佳抗氧化、抗糖尿病和β-葡萄糖醛酸酶抑制活性
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.101053
P. Gayani I. Dias , R.A. Upul J. Marapana , R.M. Udaya S.K. Rathnayaka , S.M.D. Sadhana Gayathri , N.G. Darshana Anuradha , Thilini C. Kananke , R.M. Kapila T. Rathnayaka , M.G.A. Namal Perera , Rasangani S. Sabaragamuwa , M. Nirmali Wickramaratne

Background

The influence of plant types and their ratios on the effectiveness of polyherbal formulations is a crucial yet underexplored area of research.

Objectives

This study aimed to identify the optimal ratios of Phylanthus debilis (PW), Osbeckia octrandra (HB), and Artrocarpus heterophyllus (WR) leaf powders for a polyherbal tea to achieve the best functional properties.

Material and methods

A three-level factorial design was used to examine the combined effect of three independent variables (PW, WR, and HB) on antioxidant, antidiabetic, and β-glucuronidase inhibitory activities. The variables were coded at three levels (−1, 0, +1), resulting in 10 experimental runs, with responses tested in triplicates.

Results

The highest antioxidant activity was observed in mixture 4 (PW: WR: HB = 4:1:1) for most assays. P. debilis exhibited the lowest IC50 values for α-glucosidase and β-glucuronidase inhibition, while O. octandra showed the lowest IC50 value for α-amylase inhibition compared to the mixtures. ANOVA indicated that the models and model terms of the mixture design are statistically significant (P ≤ 0.05) and the responses are well-fitted to the models (R2 = 0.8484 to 0.9993). The aqueous extractability of the polyherbal mixtures was higher than that of the individual herbs.

Conclusions

These study revealed that polyherbal formulations exhibit both synergistic and antagonistic effects on therapeutic efficacy. Mixtures 4 (PW: WR: HB = 4:1:1), 5 (PW: HB = 1:1), and 7 (PW: WR: HB = 1:1:1) were screened as the polyherbal mixtures having optimum values for selected functional properties. These combinations, along with individual herbal extracts, will undergo further testing to develop a tri-herbal tea formulation.
背景植物类型及其配比对多草药配方功效的影响是一个重要的研究领域,但尚未得到充分的探索。本研究旨在确定多草药茶中Pyylanthus debilis(PW)、Osbeckia octrandra(HB)和Artrocarpus heterophyllus(WR)叶粉的最佳配比,以实现最佳的功能特性。材料与方法采用三水平因子设计,考察三个自变量(PW、WR 和 HB)对抗氧化、抗糖尿病和β-葡萄糖醛酸酶抑制活性的综合影响。结果在大多数试验中,混合物 4(PW: WR: HB = 4:1:1)的抗氧化活性最高。与混合物相比,P. debilis 对α-葡萄糖苷酶和β-葡萄糖醛酸酶抑制作用的 IC50 值最低,而 O. octandra 对α-淀粉酶抑制作用的 IC50 值最低。方差分析表明,混合物设计的模型和模型项具有统计学意义(P ≤ 0.05),反应与模型拟合良好(R2 = 0.8484 至 0.9993)。多草药混合物的水萃取率高于单个草药的水萃取率。经筛选,混合物 4(PW:WR:HB = 4:1:1)、5(PW:HB = 1:1)和 7(PW:WR:HB = 1:1:1)是在选定功能特性方面具有最佳值的多草药混合物。这些组合以及单个草药提取物将接受进一步测试,以开发三草药茶配方。
{"title":"Identification of the best plant ratios for a polyherbal tea mix to obtain optimum antioxidant, antidiabetic, and β-glucuronidase inhibition activities","authors":"P. Gayani I. Dias ,&nbsp;R.A. Upul J. Marapana ,&nbsp;R.M. Udaya S.K. Rathnayaka ,&nbsp;S.M.D. Sadhana Gayathri ,&nbsp;N.G. Darshana Anuradha ,&nbsp;Thilini C. Kananke ,&nbsp;R.M. Kapila T. Rathnayaka ,&nbsp;M.G.A. Namal Perera ,&nbsp;Rasangani S. Sabaragamuwa ,&nbsp;M. Nirmali Wickramaratne","doi":"10.1016/j.jaim.2024.101053","DOIUrl":"10.1016/j.jaim.2024.101053","url":null,"abstract":"<div><h3>Background</h3><div>The influence of plant types and their ratios on the effectiveness of polyherbal formulations is a crucial yet underexplored area of research.</div></div><div><h3>Objectives</h3><div>This study aimed to identify the optimal ratios of <em>Phylanthus debilis</em> (PW), <em>Osbeckia octrandra</em> (HB), and <em>Artrocarpus heterophyllus</em> (WR) leaf powders for a polyherbal tea to achieve the best functional properties.</div></div><div><h3>Material and methods</h3><div>A three-level factorial design was used to examine the combined effect of three independent variables (PW, WR, and HB) on antioxidant, antidiabetic, and β-glucuronidase inhibitory activities. The variables were coded at three levels (−1, 0, +1), resulting in 10 experimental runs, with responses tested in triplicates.</div></div><div><h3>Results</h3><div>The highest antioxidant activity was observed in mixture 4 (PW: WR: HB = 4:1:1) for most assays. <em>P. debilis</em> exhibited the lowest IC<sub>50</sub> values for α-glucosidase and β-glucuronidase inhibition, while <em>O. octandra</em> showed the lowest IC<sub>50</sub> value for α-amylase inhibition compared to the mixtures. ANOVA indicated that the models and model terms of the mixture design are statistically significant (<em>P ≤ 0.05</em>) and the responses are well-fitted to the models (R<sup>2</sup> = 0.8484 to 0.9993). The aqueous extractability of the polyherbal mixtures was higher than that of the individual herbs.</div></div><div><h3>Conclusions</h3><div>These study revealed that polyherbal formulations exhibit both synergistic and antagonistic effects on therapeutic efficacy. Mixtures 4 (PW: WR: HB = 4:1:1), 5 (PW: HB = 1:1), and 7 (PW: WR: HB = 1:1:1) were screened as the polyherbal mixtures having optimum values for selected functional properties. These combinations, along with individual herbal extracts, will undergo further testing to develop a tri-herbal tea formulation.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101053"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virtual screening and network pharmacology-based synergistic coagulation mechanism identification of multiple components contained in compound Kushen Injection against hepatocellular carcinoma 基于虚拟筛选和网络药理学的复方苦参注射液抗肝癌多成分协同凝血机制鉴定
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.101055
Kejun Zhou , Mengyi Xie , Yu Liu , Lei Zheng , Juan Pu , Cheng Wang

Background

Hepatocellular carcinoma (HCC) is a primary liver malignancy commonly encountered in the setting of chronic liver disease and cirrhosis. Compound Kushen Injection (CKI) has been widely used in HCC, however, the underlying mechanisms are scarce.

Objective

To explore the molecular mechanisms of CKI for HCC.To explore the molecular mechanisms of CKI for HCC.

Materials and Methods

The chemical ingredients of CKI were reviewed from published articles and the potential targets were got from Herbal Ingredients’ Targets Platform. Coagulation-related targets were from Kyoto Encyclopedia of Genes and Genomes and HCC-related targets were from Therapeutic Target Database, Gene Expression Omnibus, and The Cancer Genome Atlas. Then the CKI-Herb-Target and CKI-Herb-Target-HCC networks were built. The shared targets between CKI and HCC were used for functional enrichment through Metascape and the shared coagulation-related target was used for molecular docking and survival analysis.

Results

A total of 23 chemical ingredients and 41 potential targets shared between CKI and HCC were obtained. The results of functional enrichment indicated that several canonical pathways of CKI mostly participated in the treatment of HCC. Furthermore, a chemical ingredient of CKI formed a stable hydrogen bond link with the ASN-189 on PLG, with a best binding energy of −4.7 kcal/mol. Finally, PLG was confirmed as the shared coagulation-related target and interrelated with the prognosis of HCC.

Conclusion

CKI probably improves HCC prognosis through PLG. Our research undoubtedly deepened the understanding of the molecular mechanism of CKI anti-HCC.
背景:肝细胞癌(HCC)是一种原发性肝脏恶性肿瘤,常见于慢性肝病和肝硬化。复方苦参注射液(CKI)已被广泛用于治疗 HCC,但其潜在机制尚不清楚:探索复方苦参注射液治疗 HCC 的分子机制:从已发表的文章中查阅CKI的化学成分,从中药成分靶点平台中获取潜在靶点。凝血相关靶点来自京都基因组百科全书,HCC相关靶点来自治疗靶点数据库、基因表达总库和癌症基因组图谱。然后建立了 CKI-Herb-Target 和 CKI-Herb-Target-HCC 网络。通过 Metascape 对 CKI 和 HCC 的共享靶点进行功能富集,并对凝血相关的共享靶点进行分子对接和生存分析:结果:共获得 23 种化学成分和 41 个潜在靶点。功能富集结果表明,CKI 的几条典型通路大多参与了 HCC 的治疗。此外,CKI的一种化学成分与PLG上的ASN-189形成了稳定的氢键连接,最佳结合能为-4.7 kcal/mol。最后,PLG被证实是凝血相关的共有靶点,并与HCC的预后相关:结论:CKI 可通过 PLG 改善 HCC 的预后。我们的研究无疑加深了对CKI抗HCC分子机制的理解。
{"title":"Virtual screening and network pharmacology-based synergistic coagulation mechanism identification of multiple components contained in compound Kushen Injection against hepatocellular carcinoma","authors":"Kejun Zhou ,&nbsp;Mengyi Xie ,&nbsp;Yu Liu ,&nbsp;Lei Zheng ,&nbsp;Juan Pu ,&nbsp;Cheng Wang","doi":"10.1016/j.jaim.2024.101055","DOIUrl":"10.1016/j.jaim.2024.101055","url":null,"abstract":"<div><h3>Background</h3><div>Hepatocellular carcinoma (HCC) is a primary liver malignancy commonly encountered in the setting of chronic liver disease and cirrhosis. Compound Kushen Injection (CKI) has been widely used in HCC, however, the underlying mechanisms are scarce.</div></div><div><h3>Objective</h3><div>To explore the molecular mechanisms of CKI for HCC.To explore the molecular mechanisms of CKI for HCC.</div></div><div><h3>Materials and Methods</h3><div>The chemical ingredients of CKI were reviewed from published articles and the potential targets were got from Herbal Ingredients’ Targets Platform. Coagulation-related targets were from Kyoto Encyclopedia of Genes and Genomes and HCC-related targets were from Therapeutic Target Database, Gene Expression Omnibus, and The Cancer Genome Atlas. Then the CKI-Herb-Target and CKI-Herb-Target-HCC networks were built. The shared targets between CKI and HCC were used for functional enrichment through Metascape and the shared coagulation-related target was used for molecular docking and survival analysis.</div></div><div><h3>Results</h3><div>A total of 23 chemical ingredients and 41 potential targets shared between CKI and HCC were obtained. The results of functional enrichment indicated that several canonical pathways of CKI mostly participated in the treatment of HCC. Furthermore, a chemical ingredient of CKI formed a stable hydrogen bond link with the ASN-189 on PLG, with a best binding energy of −4.7 kcal/mol. Finally, PLG was confirmed as the shared coagulation-related target and interrelated with the prognosis of HCC.</div></div><div><h3>Conclusion</h3><div>CKI probably improves HCC prognosis through PLG. Our research undoubtedly deepened the understanding of the molecular mechanism of CKI anti-HCC.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101055"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Withania somnifera based supplement for immunomodulatory and antiviral properties against viral infection 评估基于睡茄的补充剂对病毒感染的免疫调节和抗病毒特性。
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.100955
Dileep Kumar Verma , Abdul Hasan , Manickavasagam Rengaraju , Shree Devi , Geetika Sharma , Vimal Narayanan , Sathiyarajeswaran Parameswaran , Thirumal Kumar D , Kanakavalli Kadarkarai , Sujatha Sunil

Background

Viral mediated diseases are continuously posing potent threat to human health. Nutraceuticals are being employed as novel therapeutics during viral outbreaks. MAM granules consist of Curcuma longa, Withania somnifera, and Piper nigrum, is one such patented Siddha nutraceutical supplement that has been proposed to be a therapeutic agent against viral diseases.

Objective

We characterised MAM for their phytochemical and physicochemical properties and evaluated its cytotoxicity via in vivo acute toxicity studies using Wistar rats and by cell-based MTT assays.

Materials and Methods

The antiviral properties of the aqueous extract of MAM were investigated against SARS-CoV-2 and chikungunya virus (CHIKV). Further, using ABTS radical scavenging, SOD enzymatic assays and measurement of intracellular ROS, we investigated the antioxidant potential of MAM extract and its ingredients in RAW264.7 cells. Additionally, production of inflammatory mediators was evaluated via NO release, PGE2 production and release of pro-inflammatory cytokines (IL-1β and TNFα).

Results

The MAM granules and aqueous extracts demonstrated no significant toxicity and demonstrated potent antiviral activity during co-incubation assay with SARS-CoV-2 and CHIKV. Moreover, we observed potent antioxidant and anti-inflammatory activity of MAM extract in a dose dependent manner. Further investigations on the individual ingredients with respect to their antioxidant and anti-inflammatory activities showed that all ingredients contributed synergistically and Withania somnifera showed most potent anti-oxidant activity.

Conclusion

The overall in vitro, and in vivo analysis demonstrated that MAM granules were non-toxic and possessed potent antiviral activity. Additionally, observed significant anti-oxidant and anti-inflammatory properties of MAM suggested the modulation of innate immune response in the host validating its use as an effective nutraceutical during viral outbreaks.
背景:病毒介导的疾病不断对人类健康构成严重威胁。在病毒爆发期间,保健食品被用作新型疗法。由莪术、睡莲和胡椒组成的 MAM 颗粒就是这样一种获得专利的 Siddha 营养保健品,已被建议用作病毒性疾病的治疗剂:我们研究了 MAM 的植物化学和物理化学特性,并通过使用 Wistar 大鼠进行体内急性毒性研究和基于细胞的 MTT 试验评估了其细胞毒性:研究了 MAM 水提取物对 SARS-CoV-2 和基孔肯雅病毒 (CHIKV) 的抗病毒特性。此外,我们还使用 ABTS 自由基清除、SOD 酶测定和细胞内 ROS 测量方法,研究了 MAM 提取物及其成分在 RAW264.7 细胞中的抗氧化潜力。此外,还通过 NO 释放、PGE2 产生和促炎细胞因子(IL-1β 和 TNFα)释放评估了炎症介质的产生:结果:在与 SARS-CoV-2 和 CHIKV 的共孵育试验中,MAM 颗粒和水提取物没有显示出明显的毒性,并表现出了强大的抗病毒活性。此外,我们还观察到 MAM 提取物具有很强的抗氧化和抗炎活性,其活性与剂量有关。对各种成分的抗氧化和抗炎活性的进一步研究表明,所有成分都具有协同作用,而睡茄的抗氧化活性最强:体外和体内的总体分析表明,MAM 颗粒无毒,具有强大的抗病毒活性。此外,还观察到 MAM 具有明显的抗氧化和抗炎特性,这表明它能调节宿主的先天免疫反应,因此可在病毒爆发时用作有效的营养保健品。
{"title":"Evaluation of Withania somnifera based supplement for immunomodulatory and antiviral properties against viral infection","authors":"Dileep Kumar Verma ,&nbsp;Abdul Hasan ,&nbsp;Manickavasagam Rengaraju ,&nbsp;Shree Devi ,&nbsp;Geetika Sharma ,&nbsp;Vimal Narayanan ,&nbsp;Sathiyarajeswaran Parameswaran ,&nbsp;Thirumal Kumar D ,&nbsp;Kanakavalli Kadarkarai ,&nbsp;Sujatha Sunil","doi":"10.1016/j.jaim.2024.100955","DOIUrl":"10.1016/j.jaim.2024.100955","url":null,"abstract":"<div><h3>Background</h3><div>Viral mediated diseases are continuously posing potent threat to human health. Nutraceuticals are being employed as novel therapeutics during viral outbreaks. MAM granules consist of <em>Curcuma longa</em>, <em>Withania somnifera</em>, and <em>Piper nigrum</em>, is one such patented Siddha nutraceutical supplement that has been proposed to be a therapeutic agent against viral diseases.</div></div><div><h3>Objective</h3><div>We characterised MAM for their phytochemical and physicochemical properties and evaluated its cytotoxicity via <em>in vivo</em> acute toxicity studies using Wistar rats and by cell-based MTT assays.</div></div><div><h3>Materials and Methods</h3><div>The antiviral properties of the aqueous extract of MAM were investigated against SARS-CoV-2 and chikungunya virus (CHIKV). Further, using ABTS radical scavenging, SOD enzymatic assays and measurement of intracellular ROS, we investigated the antioxidant potential of MAM extract and its ingredients in RAW264.7 cells. Additionally, production of inflammatory mediators was evaluated via NO release, PGE2 production and release of pro-inflammatory cytokines (IL-1<em>β</em> and TNF<em>α</em>).</div></div><div><h3>Results</h3><div>The MAM granules and aqueous extracts demonstrated no significant toxicity and demonstrated potent antiviral activity during co-incubation assay with SARS-CoV-2 and CHIKV. Moreover, we observed potent antioxidant and anti-inflammatory activity of MAM extract in a dose dependent manner. Further investigations on the individual ingredients with respect to their antioxidant and anti-inflammatory activities showed that all ingredients contributed synergistically and <em>Withania somnifera</em> showed most potent anti-oxidant activity.</div></div><div><h3>Conclusion</h3><div>The overall in vitro, and <em>in vivo</em> analysis demonstrated that MAM granules were non-toxic and possessed potent antiviral activity. Additionally, observed significant anti-oxidant and anti-inflammatory properties of MAM suggested the modulation of innate immune response in the host validating its use as an effective nutraceutical during viral outbreaks.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 100955"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An exploratory single-arm open-label clinical study to evaluate the combined effect of Vamana and Sarasvata Churna in reducing excessive daytime sleepiness 一项探索性单臂开放标签临床研究,旨在评估 Vamana 和 Sarasvata Churna 在减少白天过度嗜睡方面的综合效果
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.100960
Arathy Menon , Devipriya Soman , James Chacko , P.V. Anandaraman , Mahesh C. Kundagol , K. Sreejith
<div><h3>Background</h3><p>Excessive Daytime Sleepiness (EDS) is inferred as persistent sleepiness and often a general lack of energy during the day even after apparently adequate or even prolonged nighttime sleep. The subjects may not be identifying excessive daytime sleepiness but may present as feeling tired, lack of energy etc. They may seem apparently healthy and without any other systemic illness. The prevalence was found to be as high as 18 % in 2012 in United Kingdom. Also, it is a risk factor for diseases like Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. Conventional management (Modafinil, Sodium Oxybate and Stimulants) addresses only the subjective condition in EDS and is associated with adverse effects compromising the quality of life. In the current health scenario there is a need for alternative interventions to manage this disease. On analyzing this condition through <em>Ayurveda</em>, we could understand it as <em>Nidradhikya</em> (Excessive daytime sleepiness) which is caused due to vitiated <em>Kapha Dosha</em> along with <em>Vriddha Tamoguna</em> (increased <em>Tamoguna</em>) that can be managed by <em>Shodhana</em> (biopurification) followed <em>Shamana</em> (pacification) therapies.</p></div><div><h3>Objective</h3><p>This study was aimed to assess the combined effect of <em>Vamana</em> (therapeutic vomiting) and <em>Sarasvata Churna</em> in reducing Excessive Daytime Sleepiness.</p></div><div><h3>Materials and methods</h3><p>This was a single-arm exploratory open-label clinical trial. 10 subjects having EDS diagnosed using Modified Epworth Sleepiness Scale (MESS) with a score of 10–24 with proper exclusion were recruited from OPD and IPD, Department of <em>Kāyacikitsa</em>, Amrita School of Ayurveda. All the participants were clinically examined, sought for medical history and further checked biochemically to exclude any other systemic illness that may lead to this condition. Only healthy subjects with quality night sleep (assessed by PSQI) and without any other systemic illness were selected. The treatment protocol adopted was <em>Vamana Karma</em> followed by 30 days of <em>Sarasvata Churna</em> as <em>Shamana Aushadha</em> (medicine for pacification). Assessment was done using MESS on 0<sup>th</sup> day and after 30 days of <em>Shamana Aushadha Sevana.</em> After completion of treatment, the results were statistically analysed using Wilcoxon Signed Rank Test and final conclusion was drawn.</p></div><div><h3>Results</h3><p>On analysis of the symptoms using Modified Epworth Sleepiness Scale, the mean total score reduced from 14.8 to 2.8 with 81.08 % relief in these 10 subjects and a significant p value < 0.05 after <em>Vamana</em> followed by 30 days of <em>Shamana Aushadha Sevana</em>.</p></div><div><h3>Discussion</h3><p><em>Vamana</em> helps in <em>Kapha Nirharana</em> (expelling) which removes the <em>Avarana</em> (occlusion) of <em>Manas</em> seen in <em>Nidradhikya</em>. This results
背景白天过度嗜睡(EDS)被推断为持续性嗜睡,即使在夜间睡眠明显充足甚至较长的时间后,白天仍经常出现全身乏力。受试者可能无法识别白天过度嗜睡,但可能表现为感到疲倦、乏力等。他们可能看起来很健康,没有任何其他系统疾病。2012 年,英国的发病率高达 18%。此外,它还是阿尔茨海默病、帕金森病和其他神经退行性疾病的风险因素。传统的治疗方法(莫达非尼、羟基酸钠和兴奋剂)只能解决 EDS 患者的主观症状,而且会产生不良反应,影响生活质量。在当前的健康状况下,有必要采取其他干预措施来控制这种疾病。通过阿育吠陀对这种疾病进行分析,我们可以将其理解为Nidradhikya(白天过度嗜睡),它是由于Kapha Dosha受损以及Vriddha Tamoguna(Tamoguna增加)引起的,可以通过Shodhana(生物净化)和Shamana(安抚)疗法来控制。材料和方法这是一项单臂探索性开放标签临床试验。研究人员从阿姆利塔阿育吠陀学院 Kāyacikitsa 系的门诊部和住院部招募了 10 名使用改良埃普沃思嗜睡量表 (MESS) 诊断为 10-24 分的 EDS 受试者,并进行了适当的排除。所有受试者都接受了临床检查、病史询问和进一步的生化检查,以排除任何可能导致这种情况的其他系统疾病。只有夜间睡眠质量良好(通过 PSQI 评估)且无任何其他系统疾病的健康受试者才被选中。采用的治疗方案是 Vamana Karma,然后服用 30 天 Sarasvata Churna 作为 Shamana Aushadha(安神药)。在服用 Shamana Aushadha Sevana 的第 0 天和 30 天后,使用 MESS 进行评估。治疗结束后,使用 Wilcoxon Signed Rank Test 对结果进行统计分析,并得出最终结论。讨论Vamana 有助于 Kapha Nirharana(驱逐),从而消除 Nidradhikya 中 Manas 的 Avarana(闭塞)。这就产生了 Hrit Shuddhi(心灵的纯净),有助于实现 Mano Gunas(心灵的特质)(Satvoudaryam Tamojayaha)的平衡,从而形成管理路线。作为 Shamana Aushadha 而施用的 Sarasvata Churna 具有 Medhya(促智药)、Buddhi Smriti Dhriti Vardhaka(促进智力、记忆力和耐心)的特性,目前正用于 Vicetas。Sarasvata Churna 中的大多数药物都是 Rasayana(恢复活力),通过 Rasa Dhatu 的 Prinana(滋养)给 Manas 带来 Indriya Bala(增强感官)和 Priti(蔑视)。
{"title":"An exploratory single-arm open-label clinical study to evaluate the combined effect of Vamana and Sarasvata Churna in reducing excessive daytime sleepiness","authors":"Arathy Menon ,&nbsp;Devipriya Soman ,&nbsp;James Chacko ,&nbsp;P.V. Anandaraman ,&nbsp;Mahesh C. Kundagol ,&nbsp;K. Sreejith","doi":"10.1016/j.jaim.2024.100960","DOIUrl":"10.1016/j.jaim.2024.100960","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Excessive Daytime Sleepiness (EDS) is inferred as persistent sleepiness and often a general lack of energy during the day even after apparently adequate or even prolonged nighttime sleep. The subjects may not be identifying excessive daytime sleepiness but may present as feeling tired, lack of energy etc. They may seem apparently healthy and without any other systemic illness. The prevalence was found to be as high as 18 % in 2012 in United Kingdom. Also, it is a risk factor for diseases like Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. Conventional management (Modafinil, Sodium Oxybate and Stimulants) addresses only the subjective condition in EDS and is associated with adverse effects compromising the quality of life. In the current health scenario there is a need for alternative interventions to manage this disease. On analyzing this condition through &lt;em&gt;Ayurveda&lt;/em&gt;, we could understand it as &lt;em&gt;Nidradhikya&lt;/em&gt; (Excessive daytime sleepiness) which is caused due to vitiated &lt;em&gt;Kapha Dosha&lt;/em&gt; along with &lt;em&gt;Vriddha Tamoguna&lt;/em&gt; (increased &lt;em&gt;Tamoguna&lt;/em&gt;) that can be managed by &lt;em&gt;Shodhana&lt;/em&gt; (biopurification) followed &lt;em&gt;Shamana&lt;/em&gt; (pacification) therapies.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;This study was aimed to assess the combined effect of &lt;em&gt;Vamana&lt;/em&gt; (therapeutic vomiting) and &lt;em&gt;Sarasvata Churna&lt;/em&gt; in reducing Excessive Daytime Sleepiness.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;p&gt;This was a single-arm exploratory open-label clinical trial. 10 subjects having EDS diagnosed using Modified Epworth Sleepiness Scale (MESS) with a score of 10–24 with proper exclusion were recruited from OPD and IPD, Department of &lt;em&gt;Kāyacikitsa&lt;/em&gt;, Amrita School of Ayurveda. All the participants were clinically examined, sought for medical history and further checked biochemically to exclude any other systemic illness that may lead to this condition. Only healthy subjects with quality night sleep (assessed by PSQI) and without any other systemic illness were selected. The treatment protocol adopted was &lt;em&gt;Vamana Karma&lt;/em&gt; followed by 30 days of &lt;em&gt;Sarasvata Churna&lt;/em&gt; as &lt;em&gt;Shamana Aushadha&lt;/em&gt; (medicine for pacification). Assessment was done using MESS on 0&lt;sup&gt;th&lt;/sup&gt; day and after 30 days of &lt;em&gt;Shamana Aushadha Sevana.&lt;/em&gt; After completion of treatment, the results were statistically analysed using Wilcoxon Signed Rank Test and final conclusion was drawn.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;On analysis of the symptoms using Modified Epworth Sleepiness Scale, the mean total score reduced from 14.8 to 2.8 with 81.08 % relief in these 10 subjects and a significant p value &lt; 0.05 after &lt;em&gt;Vamana&lt;/em&gt; followed by 30 days of &lt;em&gt;Shamana Aushadha Sevana&lt;/em&gt;.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;p&gt;&lt;em&gt;Vamana&lt;/em&gt; helps in &lt;em&gt;Kapha Nirharana&lt;/em&gt; (expelling) which removes the &lt;em&gt;Avarana&lt;/em&gt; (occlusion) of &lt;em&gt;Manas&lt;/em&gt; seen in &lt;em&gt;Nidradhikya&lt;/em&gt;. This results ","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 100960"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000755/pdfft?md5=614cdfc87ae8f05c98f54c92c8646586&pid=1-s2.0-S0975947624000755-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142270913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A consensus guideline on preferred items for reporting case series in homeopathy: The PITCH statement 顺势疗法病例系列报告首选项目共识指南:PITCH 声明
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.101023
Abhijit Dutta

Background

Case series is a valuable tool for sharing clinical experiences and generating research questions in the field of medicine. However, there is a lack of standardized reporting guideline for case series in homeopathy, which limits their utility and comparability. The aim of this study is to develop a reporting guideline for case series in homeopathy using a Delphi consensus process.

Method

A group of 21 experts, with experience in reviewing, publishing, or editing case reports or series in homeopathy, were participated in the study. A modified Delphi consensus process was conducted with three rounds of electronic surveys to gather feedback and opinions on the items to be included in the reporting guideline. The GRADE group's nine-point Likert scale was used to rate each item's importance and criticality.

Result

The Delphi process resulted in a consensus-based reporting guideline for case series in homeopathy, which includes recommendations for reporting case series in eleven sections, including 'Title,' 'Abstract,' 'Keywords,' 'Introduction,' 'Methods,' 'Results,' 'Discussion,' 'Conclusion,' 'Patient Perspectives,' 'References,' and 'Additional Information.' PITCH comprises a total of 59 items that achieved consensus agreement. Of these, 13 are optional items and 14 items are exclusively applicable for prospective type of case series.

Conclusion

The PITCH reporting guideline provides a structured and standardized approach for reporting case series in homeopathy. The authors, journal editors, reviewers, and educators are encouraged to adopt and implement the guideline to enhance the quality of case series in homeopathic publications.
背景病例系列是医学领域分享临床经验和提出研究问题的重要工具。然而,顺势疗法缺乏标准化的病例系列报告指南,这限制了其实用性和可比性。本研究的目的是采用德尔菲共识程序,为顺势疗法的系列病例制定报告指南。研究方法21位具有顺势疗法病例报告或系列病例审核、出版或编辑经验的专家参与了本研究。研究采用改良的德尔菲共识流程,通过三轮电子调查收集反馈意见和对报告指南中应包含项目的看法。结果德尔菲过程产生了以共识为基础的顺势疗法病例系列报告指南,其中包括11个部分的病例系列报告建议,包括 "标题"、"摘要"、"关键词"、"引言"、"方法"、"结果"、"讨论"、"结论"、"患者观点"、"参考文献 "和 "附加信息"。PITCH 共有 59 个达成共识的项目。结论PITCH报告指南为顺势疗法病例系列报告提供了结构化和标准化的方法。我们鼓励作者、期刊编辑、审稿人和教育工作者采用并执行该指南,以提高顺势疗法出版物中病例系列的质量。
{"title":"A consensus guideline on preferred items for reporting case series in homeopathy: The PITCH statement","authors":"Abhijit Dutta","doi":"10.1016/j.jaim.2024.101023","DOIUrl":"10.1016/j.jaim.2024.101023","url":null,"abstract":"<div><h3>Background</h3><div>Case series is a valuable tool for sharing clinical experiences and generating research questions in the field of medicine. However, there is a lack of standardized reporting guideline for case series in homeopathy, which limits their utility and comparability. The aim of this study is to develop a reporting guideline for case series in homeopathy using a Delphi consensus process.</div></div><div><h3>Method</h3><div>A group of 21 experts, with experience in reviewing, publishing, or editing case reports or series in homeopathy, were participated in the study. A modified Delphi consensus process was conducted with three rounds of electronic surveys to gather feedback and opinions on the items to be included in the reporting guideline. The GRADE group's nine-point Likert scale was used to rate each item's importance and criticality.</div></div><div><h3>Result</h3><div>The Delphi process resulted in a consensus-based reporting guideline for case series in homeopathy, which includes recommendations for reporting case series in eleven sections, including 'Title,' 'Abstract,' 'Keywords,' 'Introduction,' 'Methods,' 'Results,' 'Discussion,' 'Conclusion,' 'Patient Perspectives,' 'References,' and 'Additional Information.' PITCH comprises a total of 59 items that achieved consensus agreement. Of these, 13 are optional items and 14 items are exclusively applicable for prospective type of case series.</div></div><div><h3>Conclusion</h3><div>The PITCH reporting guideline provides a structured and standardized approach for reporting case series in homeopathy. The authors, journal editors, reviewers, and educators are encouraged to adopt and implement the guideline to enhance the quality of case series in homeopathic publications.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101023"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142421108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reverse pharmacology based clinical protocols for noninvasive integrative management of low grade cervical precancer lesions: Rationale and outcomes 基于反向药理学的无创综合治疗低级别宫颈癌前病变临床方案:原理和结果
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.100966
J.V. Joshi , A.A. Raut , P.H. Paradkar , S.S. Jagtap

Prevention is the most efficient and cost-effective method to combat cervical cancer for which High Risk Human Papilloma Virus (HR-HPV) infection is identified as the major causative factor. HPV vaccination is for primary prevention whereas surgical ablation of precancer is for secondary prevention after HPV infection has occurred. Screening of women for early detection of Squamous Intraepithelial Lesions (SILs) with Papanicolou smear (Pap smear) is a desirable pre-requisite. Surgical ablation which invites invasive procedures is not accessible nor affordable to the larger section of the population. We propose here a non-invasive integrative management approach for the early phase of cervical pre-cancer.

In tune with the reverse pharmacology approach, ‘experience-exploration- experimentation’, we have conducted five clinical studies related to Turmeric extracts for chemo-preventive activity and non-surgical feasibility. We were able to achieve arrest or regression in Low-grade SILs in all 41 women participating in these studies.

The unique features of this integrative management approach were i) Avoidance of surgery-associated trauma, cost and complications ii) Standard of care for associated genital infections iii) Feasibility when surgery was not accessible iv) Scope for repeating the noninvasive treatment.

高危人乳头瘤病毒(HR-HPV)感染是宫颈癌的主要致病因素,而预防是防治宫颈癌最有效、最具成本效益的方法。HPV 疫苗接种用于一级预防,而癌前病变的手术消融则用于 HPV 感染后的二级预防。通过巴氏涂片对妇女进行筛查以早期发现鳞状上皮内病变(SIL)是一个理想的先决条件。手术消融需要进行侵入性操作,对于大多数人来说既不方便,也负担不起。根据 "经验-探索-实验 "的反向药理学方法,我们对姜黄提取物的化学预防活性和非手术可行性进行了五项临床研究。这种综合治疗方法的独特之处在于:i) 避免了手术相关的创伤、费用和并发症 ii) 对相关生殖器感染的标准护理 iii) 在无法进行手术时的可行性 iv) 可重复非侵入性治疗。
{"title":"Reverse pharmacology based clinical protocols for noninvasive integrative management of low grade cervical precancer lesions: Rationale and outcomes","authors":"J.V. Joshi ,&nbsp;A.A. Raut ,&nbsp;P.H. Paradkar ,&nbsp;S.S. Jagtap","doi":"10.1016/j.jaim.2024.100966","DOIUrl":"10.1016/j.jaim.2024.100966","url":null,"abstract":"<div><p>Prevention is the most efficient and cost-effective method to combat cervical cancer for which High Risk Human Papilloma Virus (HR-HPV) infection is identified as the major causative factor. HPV vaccination is for primary prevention whereas surgical ablation of precancer is for secondary prevention after HPV infection has occurred. Screening of women for early detection of Squamous Intraepithelial Lesions (SILs) with Papanicolou smear (Pap smear) is a desirable pre-requisite. Surgical ablation which invites invasive procedures is not accessible nor affordable to the larger section of the population. We propose here a non-invasive integrative management approach for the early phase of cervical pre-cancer.</p><p>In tune with the reverse pharmacology approach, ‘experience-exploration- experimentation’, we have conducted five clinical studies related to Turmeric extracts for chemo-preventive activity and non-surgical feasibility. We were able to achieve arrest or regression in Low-grade SILs in all 41 women participating in these studies.</p><p>The unique features of this integrative management approach were i) Avoidance of surgery-associated trauma, cost and complications ii) Standard of care for associated genital infections iii) Feasibility when surgery was not accessible iv) Scope for repeating the noninvasive treatment.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 100966"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000810/pdfft?md5=c852cad33b0666ba99e0056247e76456&pid=1-s2.0-S0975947624000810-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142135838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of congenitally fused cervical vertebrae with Ayurveda intervention - A case report 通过阿育吠陀干预治疗先天性颈椎融合--病例报告
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.100964
Ranjita Ekka , Shakti Bhushan , Ekta Ekta , Parvathy G. Nair , Amit Kumar Dixit , P.V.V. Prasad

A 42-year-old male patient presented with complaints of vertigo, neck pain, swallowing difficulties, and difficulty in maintaining an upright posture. The patient took allopathic consultation for the complaints and was advised to undergo MDCT scan of brain, hematological and audiological evaluations. No abnormalities were detected in the investigations and he was given some medications for symptomatic management. As no relief was noted, the patient took an Ayurveda consultation. After clinical evaluation, the patient was advised to perform an X-ray of the cervical spine and was diagnosed with congenital block vertebrae at C3 – C4 vertebral bodies and posterior appendages with hypoplastic intervening disc space. He was advised to take Ekangveerarasa 250 mg BD before food with honey, Trayodashang guggulu 1 gm BD after food, Vishatinduka vati 250 mg BD after food, Aswagandha churna 3 gm BD after food with milk.The patient was also advised to do light massage and mild hot fomentation in the neck region twice a day with Mahavishagarbha oil. Remarkable relief was observed with all signs and symptoms including a reduction of score in the Neck Disability Index (NDI) within a very short duration of treatment. Considerable improvements were noted in the quality of life of the patient as confirmed by the WHO QOL BREF score. This case report shows that Ayurveda can offer safer and more effective symptomatic treatment for conditions like congenitally fused vertebrae.

一名 42 岁的男性患者主诉眩晕、颈部疼痛、吞咽困难和难以保持直立姿势。患者就其主诉接受了全科咨询,医生建议其接受脑部 MDCT 扫描、血液学和听力评估。检查未发现异常,医生给他服用了一些药物对症治疗。由于症状没有得到缓解,患者接受了阿育吠陀咨询。在进行临床评估后,医生建议患者进行颈椎 X 光检查,并诊断其 C3 - C4 椎体和后附属椎体存在先天性椎体阻滞,椎间盘间隙发育不良。医生建议他饭前用蜂蜜服用 Ekangveerarasa 250 毫克 BD,饭后服用 Trayodashang guggulu 1 克 BD,饭后服用 Vishatinduka vati 250 毫克 BD,饭后用牛奶服用 Aswagandha churna 3 克 BD。在很短的治疗时间内,所有症状和体征都明显缓解,包括颈部残疾指数(NDI)得分降低。经世界卫生组织 QOL BREF 评分证实,患者的生活质量得到了显著改善。本病例报告表明,阿育吠陀可以为先天性椎体融合等疾病提供更安全、更有效的对症治疗。
{"title":"Management of congenitally fused cervical vertebrae with Ayurveda intervention - A case report","authors":"Ranjita Ekka ,&nbsp;Shakti Bhushan ,&nbsp;Ekta Ekta ,&nbsp;Parvathy G. Nair ,&nbsp;Amit Kumar Dixit ,&nbsp;P.V.V. Prasad","doi":"10.1016/j.jaim.2024.100964","DOIUrl":"10.1016/j.jaim.2024.100964","url":null,"abstract":"<div><p>A 42-year-old male patient presented with complaints of vertigo, neck pain, swallowing difficulties, and difficulty in maintaining an upright posture. The patient took allopathic consultation for the complaints and was advised to undergo MDCT scan of brain, hematological and audiological evaluations. No abnormalities were detected in the investigations and he was given some medications for symptomatic management. As no relief was noted, the patient took an Ayurveda consultation. After clinical evaluation, the patient was advised to perform an X-ray of the cervical spine and was diagnosed with congenital block vertebrae at C3 – C4 vertebral bodies and posterior appendages with hypoplastic intervening disc space. He was advised to take Ekangveerarasa 250 mg BD before food with honey, Trayodashang guggulu 1 gm BD after food, Vishatinduka vati 250 mg BD after food, Aswagandha churna 3 gm BD after food with milk.The patient was also advised to do light massage and mild hot fomentation in the neck region twice a day with Mahavishagarbha oil. Remarkable relief was observed with all signs and symptoms including a reduction of score in the Neck Disability Index (NDI) within a very short duration of treatment. Considerable improvements were noted in the quality of life of the patient as confirmed by the WHO QOL BREF score. This case report shows that Ayurveda can offer safer and more effective symptomatic treatment for conditions like congenitally fused vertebrae.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 100964"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000792/pdfft?md5=c0ad21ce9ab5d86ce9ddb5e176cdebce&pid=1-s2.0-S0975947624000792-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Product development and characterization of a lipid-based Ayurvedic polyherbal formulation: Kalyanaka Ghrita 基于脂质的阿育吠陀多草药配方的产品开发和特征描述:Kalyanaka Ghrita
IF 1.7 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-09-01 DOI: 10.1016/j.jaim.2024.101011
Yashika Singh , Amzad Ali Ansari , Rajendra Prasad Sharma , Saroj Moreshwar Parhate , Thakur Rakesh Singh

Background

Kalyanaka Ghrita (KG) is polyherbal oleaginous medicament consisting of extracts from twenty-eight different plants, indicated for management of psychosomatic disorders like Unmada (Schizophrenia), Apasmara (Epilepsy) and numerous other ailments.

Objective

To develop and validate standard manufacturing procedure of KG by following Ayurvedic principles in three batches to ensure process uniformity and standards.

Materials and methods

Three batches of KG were prepared by adopting principles of Ashtanga Hrudya and Ayurvedic Formulary of India to ensure consistency in manufacturing process. Observations during process such as temperature, duration were recorded. KG was subjected to chief desired characteristics, organoleptic (color, odour, taste, texture, touch), physicochemical (acid value, peroxide value, iodine value, saponification value, loss on drying, refractive index, specific gravity, mineral oil, rancidity test, viscosity) as per pharmacopeial standard. Chromatographic screening and fingerprinting of KG were conducted through GCMS whereas quantification of curcumin and chebulagic acid biomarkers were assessed through HPLC.

Results

Average yield of KG was 83.41%, with average intermittent heating duration of 20.35 h subsequently divided into three days. Temperature throughout preparation ranged from 66 °C to 101 °C. KG was pale olive in colour, exhibiting pleasant taste, characteristic smell, and soft texture. Organoleptic and physicochemical characters were comparable for three batches of KG while safety parameters were found within permissible limits.

Conclusion

Pharmaceutical standardization of Kalyanaka Ghrita is necessary for establishing biological and chemical profile of formulations. Present study recommends use of coarse powdered ingredients for optimal yield during pharmaceutical process, and heating up to Madhyama Paka stage calibrated over three days with average temperature of 85 °C. The data obtained from this study may contribute to future research and development activities, serving as a basis for manufacturing standards of KG.
背景Kalyanaka Ghrita(KG)是一种多草本含油药物,由 28 种不同植物的提取物组成,适用于治疗 Unmada(精神分裂症)、Apasmara(癫痫)等心身疾病和许多其他疾病。材料和方法采用 Ashtanga Hrudya 和印度阿育吠陀处方集的原则制备了三批 KG,以确保生产过程的一致性。对生产过程中的温度、持续时间等进行了观察记录。根据药典标准,对 KG 进行了所需的主要特征、感官(颜色、气味、味道、质地、触感)和理化(酸 值、过氧化值、碘值、皂化值、干燥损失、折射率、比重、矿物油、酸败试验、粘度)测试。结果 KG 的平均产量为 83.41%,平均间歇加热时间为 20.35 小时,随后分为三天。整个制备过程的温度范围为 66 °C 至 101 °C。KG 呈浅橄榄色,口感宜人,气味独特,质地柔软。三个批次的 Kalyanaka Ghrita 的感官和理化特性相当,而安全参数则在允许范围内。本研究建议在制药过程中使用粗粉末成分以获得最佳产量,并在平均温度为 85 °C 的情况下加热至 Madhyama Paka 阶段,校准时间为三天。本研究获得的数据可能有助于未来的研发活动,并可作为 KG 生产标准的基础。
{"title":"Product development and characterization of a lipid-based Ayurvedic polyherbal formulation: Kalyanaka Ghrita","authors":"Yashika Singh ,&nbsp;Amzad Ali Ansari ,&nbsp;Rajendra Prasad Sharma ,&nbsp;Saroj Moreshwar Parhate ,&nbsp;Thakur Rakesh Singh","doi":"10.1016/j.jaim.2024.101011","DOIUrl":"10.1016/j.jaim.2024.101011","url":null,"abstract":"<div><h3>Background</h3><div><em>Kalyanaka Ghrita</em> (KG) is polyherbal oleaginous medicament consisting of extracts from twenty-eight different plants, indicated for management of psychosomatic disorders like <em>Unmada</em> (Schizophrenia), <em>Apasmara</em> (Epilepsy) and numerous other ailments.</div></div><div><h3>Objective</h3><div>To develop and validate standard manufacturing procedure of KG by following <em>Ayurvedic</em> principles in three batches to ensure process uniformity and standards.</div></div><div><h3>Materials and methods</h3><div>Three batches of KG were prepared by adopting principles of <em>Ashtanga Hrudya</em> and Ayurvedic Formulary of India to ensure consistency in manufacturing process. Observations during process such as temperature, duration were recorded. KG was subjected to chief desired characteristics, organoleptic (color, odour, taste, texture, touch), physicochemical (acid value, peroxide value, iodine value, saponification value, loss on drying, refractive index, specific gravity, mineral oil, rancidity test, viscosity) as per pharmacopeial standard. Chromatographic screening and fingerprinting of KG were conducted through GCMS whereas quantification of curcumin and chebulagic acid biomarkers were assessed through HPLC.</div></div><div><h3>Results</h3><div>Average yield of KG was 83.41%, with average intermittent heating duration of 20.35 h subsequently divided into three days. Temperature throughout preparation ranged from 66 °C to 101 °C. KG was pale olive in colour, exhibiting pleasant taste, characteristic smell, and soft texture. Organoleptic and physicochemical characters were comparable for three batches of KG while safety parameters were found within permissible limits.</div></div><div><h3>Conclusion</h3><div>Pharmaceutical standardization of <em>Kalyanaka Ghrita</em> is necessary for establishing biological and chemical profile of formulations. Present study recommends use of coarse powdered ingredients for optimal yield during pharmaceutical process, and heating up to <em>Madhyama Paka</em> stage calibrated over three days with average temperature of 85 °C. The data obtained from this study may contribute to future research and development activities, serving as a basis for manufacturing standards of KG.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 5","pages":"Article 101011"},"PeriodicalIF":1.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142433464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Ayurveda and Integrative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1